Polpharma Biologics Secures FDA and EMA Review for PB016
ROTKREUZ, Switzerland, July 31, 2026 Polpharma Biologics International AG announced that the U.S. Food and Drug Administration (FDA) and...
IBD
Advertisement
Caldera, Synlogic Unite in $278M Biotech Merger
CAMBRIDGE, Mass., July 29, 2026 Synlogic, Inc. and Caldera Therapeutics, Inc. have entered into a definitive all-stock merger agreement...
Belay Announces NCCN Recommendation for CSF-Based Profiling in High-Grade Gliomas
CHICAGO, Ill., June 20, 2026 The National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines in Oncology...
cAMPfield Launches With $180M to Advance Oral IBD Therapy
SAN DIEGO, Calif., June 20, 2026 cAMPfield Therapeutics has officially emerged from stealth with a $180 million Series A...
Mabwell Receives NMPA Clearance for 9MW5211 in Inflammatory Bowel Disease
SHANGHAI, China, June 5, 2026 Mabwell announced that China’s National Medical Products Administration (NMPA) has granted Investigational New Drug...
Advertisements
Abivax’s Obefazimod Delivers Landmark Phase 3 Success in Ulcerative Colitis
PARIS, France, June 1, 2026 Abivax announced positive topline results from its pivotal Phase 3 ABTECT maintenance trial evaluating...
Abivax Reports Strong Three-Year Remission Results for Obefazimod in Ulcerative Colitis
PARIS, France, May 22, 2026 Abivax announced new three-year interim data from Study 108 showing that obefazimod maintained durable...
Spyre to Reveal SKYLINE UC Trial Results on April 13
Waltham, Massachusetts | April 10, 2026 Spyre Therapeutics Inc. has announced that it will report topline results from Part...
Quotient Therapeutics, Merck Sign $2.2B IBD Deal
CAMBRIDGE, MASSACHUSETTS, March 24, 2026 Quotient Therapeutics has announced a multi-year research collaboration with Merck & Co. to discover...
FDA Updates RINVOQ® Label for Inflammatory Bowel Disease Use
NORTH CHICAGO, Illinois, October 13, 2025 – AbbVie Inc. (NYSE: ABBV) announced that the U.S. Food and Drug Administration...
Advertisement
